Replies to post #42012 on Humanigen Inc (HGENQ)

[InfinitePhoenix4]

I see the value in subsidiaries(specifically, the Australian one )as more immediate and substantive compared to the IP with Taran . As it is only holdi ( IP and inventory). The only potential revenue for Taran will be licensing fees from future sales from the subsidiaries of Humanigen .. This structure essentially separates the IP company from the operating. Entities . This was also necessary for providing the DIP financing . Taran does not have access to the rights that the Australian company has and data on clinical trials for a potential biologic submission as it was excluded from the sale to Taran .